The bioactivity of recombinant mIFN-γ was determined in a virus protection assay. L-929 cells were pretreated with increasing concentrations of mIFN-γ (started at 25 pg/ml). Cells were then inoculated with encephalomyocarditis virus (EMCV). The OD590 was determined for the surviving cells.
The purity of recombinant mIFN-γ was determined by SDS-PAGE of 1 µg reduced (+) and non-reduced (-) recombinant mIFN-γ and staining overnight with Coomassie Blue.
Western blot analysis of extracts from L-929 cells, untreated or treated with mIFN-γ for 20 minutes, using Phospho-Stat1 (Tyr701) (D4A7) Rabbit mAb #7649 (upper) and Stat1 Antibody #9172 (lower).
Working concentration of mIFN-γ generally ranges from 0.1-10 ng/ml.
Recombinant mouse IFN-γ is supplied as lyophilized material that is very stable at -20°C. It is recommended to reconstitute with sterile water at a concentration of 0.1 mg/ml which can be further diluted in aqueous solutions as needed. Addition of a carrier protein (0.1% HSA or BSA) is recommended for long term storage.
A greater than 95% purity was determined by SDS-PAGE.
Less than or equal to 1 EU / 1 μg mIFN-γ.
The bioactivity of mIFN-γ was determined in a virus protection assay. The biological activity of each lot is greater than or equal to 1.0 x 10^7 units/mg.
Recombinant mouse IFN-γ was expressed in E. coli and is supplied in a lyophilized form.
IFN-γ plays key roles in both the innate and adaptive immune response. IFN-γ activates the cytotoxic activity of innate immune cells such as macrophages and NK cells (1,2). IFN-γ production by NK cells and antigen-presenting cells (APCs) promotes cell-mediated adaptive immunity by inducing IFN-γ production by T lymphocytes, increased class I and class II MHC expression, and enhancing peptide antigen presentation (1). The anti-viral activity of IFN-γ is due to its induction of PKR and other regulatory proteins. Binding of IFN-γ to the IFNGR1/IFNGR2 complex promotes dimerization of the receptor complexes. Binding induces a conformational change in receptor intracellular domains and signaling involves Jak1, Jak2, and Stat1 (3). The critical role of IFN-γ in amplification of immune surveillance and function is supported by increased susceptibility to pathogen infection by IFN-γ or IFNGR knockout mice, and in humans with inactivating mutations in IFNGR1 or IFNGR2. IFN-γ also appears to have a role in atherosclerosis (4).
Explore pathways + proteins related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.